Document Detail

Treatment options in pediatric epilepsy syndromes.
MedLine Citation:
PMID:  12446225     Owner:  NLM     Status:  MEDLINE    
Recent evidence suggests that various epilepsy syndromes respond differently to antiepileptic drugs. It follows that a more precise diagnosis, together with a better understanding of AED mechanisms of action, enables them to be used more specifically, and therefore more effectively. Patient characteristics including age of onset, seizure frequency, EEG data and the findings of imaging studies, provide diagnostic pointers which enable the physician to reach a syndrome diagnosis and to choose the most appropriate AED for the individual patient. Home videotapes of paroxysmal events are becoming increasingly available and are often of great assistance. Parents should be encouraged to record their children's attacks. Careful history-taking and correct interpretation of clinical data remain the cornerstones of accurate diagnosis and successful treatment. However, the specificity of antiepileptic drugs is relatively limited and often pharmacotherapy should start using an agent with a broad spectrum of activity appropriate for the primary seizure type. It is in fact common that several antiepileptic agents have similar or identical effectiveness for one particular form of epilepsy. Therefore, the eventual side effects and the greater or lesser difficulties in handling the drug play an essential role in the choice of a therapeutic agent. Polypharmacy should be avoided and surgery should be considered early for selected patients, particularly children, who fail to respond to an appropriate drug trial. Correct diagnosis and the first drug(s) used may have a crucial impact on the evolution of given epilepsy. One major emphasis in the management of epilepsy is on information that should be complete, adapted to the level of understanding, and objective, although given in a positive manner. The understanding and cooperation of children and their families is clearly decisive for the success of therapy, and this requires a confident relationship between the physician and the patient. Current knowledge, on antiepileptic drugs options in paediatric epilepsy syndromes, is discussed.
Alexis Arzimanoglou
Related Documents :
6816335 - Early prognosis of epilepsy.
19860705 - Sugar sulfamates for seizure control: discovery and development of topiramate, a struct...
24835295 - Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
24562495 - William t. carpenter jr: 35 years of clinical trials.
10379475 - A clinical approach to management of patients with non-steroidal anti-inflammatory gast...
10097965 - A collaborative evaluation of a needle exchange program for youth.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Epileptic disorders : international epilepsy journal with videotape     Volume:  4     ISSN:  1294-9361     ISO Abbreviation:  Epileptic Disord     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-11-26     Completed Date:  2003-01-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100891853     Medline TA:  Epileptic Disord     Country:  France    
Other Details:
Languages:  eng     Pagination:  217-25     Citation Subset:  IM    
Epilepsy Unit, Department of Child Neurology and Metabolic Disorders, Children's University Hôpital Robert-Debré, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenocorticotropic Hormone / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Epilepsy / classification,  diagnosis,  therapy*
Hydrocortisone / therapeutic use*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 50-23-7/Hydrocortisone; 9002-60-2/Adrenocorticotropic Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Idiopathic generalised epilepsies with 3 Hz and faster spike wave discharges: a population-based stu...
Next Document:  Chromogranin A: a marker of neuroendocrine tumors